<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1715">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05138835</url>
  </required_header>
  <id_info>
    <org_study_id>2020-ALG-BTX</org_study_id>
    <nct_id>NCT05138835</nct_id>
  </id_info>
  <brief_title>BOTOX® Cosmetic and Skin Health.</brief_title>
  <official_title>A Randomized, Double Blind Evaluation of the Effects of BOTOX® Cosmetic on Skin Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andreas Nikolis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erevna Innovations Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two cohort, randomized, double blind, single center study to evaluate the effects&#xD;
      of Botox Cosmetic (BTX) on sebum protection. Thirty-four female subjects with&#xD;
      moderate-to-high skin sebum concentration will be recruited and randomized in a 1:1 ratio to&#xD;
      treatment groups.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2021</start_date>
  <completion_date type="Anticipated">December 11, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 11, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Skin quality assessment</measure>
    <time_frame>Baseline versus Week 4</time_frame>
    <description>Reduction in sebum</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Oily Skin</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive BTX in the glabella and forehead regions, using a traditional injection technique commonly utilized in aesthetic medicine. The traditional injection technique will deposit the neurotoxin into the targeted muscles; with up to 24 units being injected into the forehead and 20 units in the glabella.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive the traditional, deep injection technique, in addition to a superficial intradermal injection technique, which uses micro-aliquots of toxin. The superficial technique will deposit 0.1 units of toxin at 5mm intervals, at the level of the deep dermis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botox Cosmetic</intervention_name>
    <description>BOTOX® Cosmetic is approved and commercially available for use in Canada.&#xD;
BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe frown lines between the eyebrows, crow's feet lines, and forehead lines in adults.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age above 18 years.&#xD;
&#xD;
          2. Female sex.&#xD;
&#xD;
          3. A SebumeterTM score &gt;66ug/cm2 at Baseline.&#xD;
&#xD;
          4. Ability to adequately understand the verbal explanations and the written subject&#xD;
             information provided in local language and ability and willingness to give consent to&#xD;
             participate in the study.&#xD;
&#xD;
          5. Signed and dated informed consent to participate in the study and unrestricted use of&#xD;
             facial images for marketing purpose.&#xD;
&#xD;
          6. If female of childbearing potential: a negative urine pregnancy test before all&#xD;
             treatments is required.&#xD;
&#xD;
          7. Subject agrees to use the same topical cosmetic products (e.g., cleansers,&#xD;
             moisturizers) throughout the duration of the trial, and at least for 30 days prior to&#xD;
             enrolment.&#xD;
&#xD;
          8. Subject is on a stable diet and is not planning any major dietary changes throughout&#xD;
             the duration of the trial.&#xD;
&#xD;
          9. Subject is not planning on undergoing any major hormonal changes throughout the&#xD;
             duration of the study (e.g., menopause, change in medications).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current Pregnancy or lactation [sexually active women of childbearing age must agree&#xD;
             to use medically acceptable methods of contraception for the duration of this study&#xD;
             (e.g., oral contraceptives, condoms, intrauterine device, shot/injection, patch)];&#xD;
&#xD;
          2. Patients meeting any official BOTOX® Cosmetic contra-indications;&#xD;
&#xD;
          3. Inability to comply with follow-up and abstain from other treatments in the region of&#xD;
             interest during the study period;&#xD;
&#xD;
          4. Heavy smokers, classified as smoking more than 12 cigarettes per day;&#xD;
&#xD;
          5. History of severe or multiple allergies manifested by anaphylaxis;&#xD;
&#xD;
          6. Previous tissue revitalization therapy in the treatment area within 6 months before&#xD;
             treatment with laser or light, mesotherapy, radiofrequency, ultrasound, cryotherapy,&#xD;
             chemical peeling, or dermabrasion;&#xD;
&#xD;
          7. Previous treatment with neurotoxins in the area under assessment, within 6 months&#xD;
             prior to enrolment;&#xD;
&#xD;
          8. Previous treatment with soft tissue fillers in the area under assessment, within 6&#xD;
             months prior to enrolment;&#xD;
&#xD;
          9. Subjects presenting with known allergy to BOTOX® Cosmetic.&#xD;
&#xD;
         10. Subjects presenting with porphyria.&#xD;
&#xD;
         11. Subjects with active disease, such as inflammation, infection or tumors, in or near&#xD;
             the intended treatment site.&#xD;
&#xD;
         12. History of bleeding disorders or treatment with thrombolytics, anticoagulants, or&#xD;
             inhibitors of platelet aggregation (e.g. Aspirin or other non-steroid&#xD;
             anti-inflammatory drugs [NSAIDs]), within 2 weeks before treatment.&#xD;
&#xD;
         13. Subjects using immunosuppressants.&#xD;
&#xD;
         14. Subjects prescribed systematic or topical (in the area under assessment) antibiotics&#xD;
             within 1 month of enrolment.&#xD;
&#xD;
         15. Tattoos, piercings or visible markings that in the treating investigator's opinion,&#xD;
             may interfere with results or assessments.&#xD;
&#xD;
         16. Cancer or precancer in the treatment area, e.g. actinic keratosis.&#xD;
&#xD;
         17. Patients with a tendency to form hypertrophic scars or any other healing disorders.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Nikolis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erevna Innovations Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Nikolis</last_name>
    <phone>514-488-0163</phone>
    <email>research@vicpark.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Erevna Innovations Inc</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3R 3A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Nikolis, MD</last_name>
      <phone>514-488-0163</phone>
      <email>research@vicpark.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 17, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Erevna Innovations Inc.</investigator_affiliation>
    <investigator_full_name>Andreas Nikolis</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

